Nature Search

Pathological sequelae of long-haul COVID

It is increasingly obvious that individuals are experiencing post-COVID-19 syndromes, or ‘long-haul COVID’. Here, Merad and Mehandru eview currently available knowledge of the underlying pathophysiological mechanisms of these sequelae, elaborating on persistent inflammation, induced autoimmunity and putative viral reservoirs.

Saurabh Mehandru
Miriam Merad
Reviews01 Feb 2022
Nature Immunology

Volume: 23, P: 194-202
IBD across the age spectrum—is it the same disease?

IBD is a chronic disorder with disease onset ranging from early childhood to beyond the sixth decade of life. This Review provides an overview of the differences in epidemiology, clinical characteristics, and natural history of paediatric, adult, and elderly-onset IBD. In addition, potential differences in host–gene–microbial interactions according to age are highlighted.

Joannie Ruel
Darren Ruane
Jean-Frédéric Colombel
Reviews17 Dec 2013
Nature Reviews Gastroenterology & Hepatology

Volume: 11, P: 88-98
Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity

Multi-modal profiling reveals major alterations in colonic B cells in patients with ulcerative colitis, including reduced clonal diversity of plasma cells, and suggests that circulating gut-homing plasmablasts could serve as a biomarker for disease activity.

Mathieu Uzzan
Jerome C. Martin
Saurabh Mehandru
Research21 Feb 2022
Nature Medicine

Volume: 28, P: 766-779
Evolution of antibody immunity to SARS-CoV-2

In a cohort of 87 individuals with COVID-19, the memory B cell response at 6.2 months after the onset of disease evolves in a manner that is consistent with the persistence of SARS-CoV-2 antigen.

Christian Gaebler
Zijun Wang
Michel C. Nussenzweig
Research18 Jan 2021
Nature

Volume: 591, P: 639-644
Gastrointestinal post-acute COVID-19 syndrome

The definition of gastrointestinal involvement in post-acute COVID-19 syndrome, its frequency and its pathophysiology are still not completely understood. Here, we discuss the emerging evidence supporting immunological signatures and the unique nature of the gastrointestinal tract in this syndrome.

Hadar Meringer
Saurabh Mehandru
Comments & Opinion05 Apr 2022
Nature Reviews Gastroenterology & Hepatology

Volume: 19, P: 345-346
Author Correction: SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)

Amy D. Proal
Michael B. VanElzakker
E. John Wherry
Amendments and Corrections18 Sept 2023
Nature Immunology

Volume: 24, P: 1778
Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Thomas U. Marron
Matthew D. Galsky
Miriam Merad
Amendments and Corrections18 Jul 2022
Nature Medicine

Volume: 28, P: 1723
Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children

Multisystem inflammatory syndrome in children (MIS-C) onsets in COVID-19 patients with manifestations similar to Kawasaki disease (KD). Here the author probe the peripheral blood transcriptome of MIS-C patients to find signatures related to natural killer (NK) cell activation and CD8+ T cell exhaustion that are shared with KD patients.

Noam D. Beckmann
Phillip H. Comella
Alexander W. Charney
ResearchOpen Access11 Aug 2021
Nature Communications

Volume: 12, P: 1-15
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Window-of-opportunity trials, during which patients receive short-duration pre-surgical therapies, provide a platform for understanding the therapies’ mechanisms of action, but will require a paradigm shift in trial design, specimen collection and analysis.

Thomas U. Marron
Matthew D. Galsky
Miriam Merad
Comments & Opinion28 Mar 2022
Nature Medicine

Volume: 28, P: 626-629
The intestinal barrier, an arbitrator turned provocateur in IBD

Key studies published in 2020 demonstrate that an impaired intestinal barrier precedes clinical diagnosis of inflammatory bowel disease (IBD) by years. Furthermore, studies identify novel regulators of the intestinal barrier, including intestinal macrophages and diurnal variations of diet–microbiome interactions, which could be future therapeutic strategies for IBD.

Saurabh Mehandru
Jean-Frederic Colombel
News & Views14 Dec 2020
Nature Reviews Gastroenterology & Hepatology

Volume: 18, P: 83-84
Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19

Graham J. Britton
Alice Chen-Liaw
Jeremiah J. Faith
ResearchOpen Access25 Jun 2021
Scientific Reports

Volume: 11, P: 1-13
Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae

Transcriptomic analyses of acute phase whole blood from a large cohort of patients with COVID-19 identify molecular determinants of post-infection long-term sequelae.

Ryan C. Thompson
Nicole W. Simons
Noam D. Beckmann
ResearchOpen Access08 Dec 2022
Nature Medicine

Volume: 29, P: 236-246
Author Correction: Sampling the host response to SARS-CoV-2 in hospitals under siege

Alexander W. Charney
Nicole W. Simons
Miriam Merad
Amendments and Corrections05 Feb 2021
Nature Medicine

Volume: 27, P: 560
Advancing scientific knowledge in times of pandemics

This Comment article from the Precision Immunology Institute at the Icahn School of Medicine (PrIISM), New York, describes their efforts to provide critical reviews of COVID-19 articles posted daily on the preprint servers bioRxiv and medRxiv.

Nicolas Vabret
Robert Samstein
Uri Laserson
Comments & Opinion23 Apr 2020
Nature Reviews Immunology

Volume: 20, P: 338
Author Correction: Sampling the host response to SARS-CoV-2 in hospitals under siege

Alexander W. Charney
Nicole W. Simons
Miriam Merad
Amendments and Corrections21 Aug 2020
Nature Medicine

Volume: 26, P: 1493
SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)

Proal and colleagues review the evidence for long-term persistence of coronavirus SARS-CoV-2 in tissues of infected individuals and discuss how this viral reservoir may contribute to the pathogenesis of post-acute sequelae of COVID-19 (PASC).

Amy D. Proal
Michael B. VanElzakker
E. John Wherry
Reviews04 Sept 2023
Nature Immunology

Volume: 24, P: 1616-1627
The appendix and ulcerative colitis — an unsolved connection

The appendix is thought to have a role in the pathogenesis of ulcerative colitis but the association remains unclear. In this Perspective, the authors consider the biology of the appendix with respect to its immunological function and the microbiome, and how this relates to its possible involvement in ulcerative colitis.

Manasi Agrawal
Kristine H. Allin
Jean-Frederic Colombel
Reviews20 Apr 2023
Nature Reviews Gastroenterology & Hepatology

Volume: 20, P: 615-624
Deciphering the different phases of preclinical inflammatory bowel disease

Inflammatory bowel disease (IBD) is an immune-mediated inflammatory disease (IMID). Here, the authors review evidence on the preclinical phase of IBD, outlining and describing the proposed at-risk, initiation and expansion phases. Overlap with other IMIDs is discussed alongside the possible future directions for research into preclinical IBD.

Jonas J. Rudbaek
Manasi Agrawal
Tine Jess
Reviews10 Nov 2023
Nature Reviews Gastroenterology & Hepatology

Volume: 21, P: 86-100
Sampling the host response to SARS-CoV-2 in hospitals under siege

Alexander W. Charney
Nicole W. Simons
Miriam Merad
Correspondence27 Jul 2020
Nature Medicine

Volume: 26, P: 1157-1158
A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract

D Ruane
Y Do
S Mehandru
Research06 Jan 2016
Mucosal Immunology

Volume: 9, P: 1340-1352
Phenotype and function of nasal dendritic cells

H Lee
D Ruane
S Mehandru
Research11 Feb 2015
Mucosal Immunology

Volume: 8, P: 1083-1098
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease

IL-12 and IL-23 have been implicated in inflammatory bowel disease. In this Review, Vande Casteele and colleagues summarize the mechanistic role of IL-12 and IL-23 in inflammatory bowel disease, and discuss the clinical development of drugs targeting IL-12 and/or IL-23.

Bram Verstockt
Azucena Salas
Stefania Vetrano
Reviews17 Apr 2023
Nature Reviews Gastroenterology & Hepatology

Volume: 20, P: 433-446
The current state of the art for biological therapies and new small molecules in inflammatory bowel disease

Sudarshan Paramsothy
Adam K. Rosenstein
Jean-Frederic Colombel
Reviews15 Jun 2018
Mucosal Immunology

Volume: 11, P: 1558-1570

Search

Filter By:

Search

Quick links